Since the study reported in the manuscript is a Systematic Review (SR), only data already published, without any ethical or legal restriction, have been presented. The final database with the results of the SR is available in the Supporting Information files.

Introduction {#sec001}
============

During the last decades, progress in the food industry and globalization have markedly increased the exposure to new allergenic sources that not always are adequately pointed out \[[@pone.0203671.ref001]\]. Coupled with changes in eating habits, including widespread consumption of raw, marinated or smoked fish, a quota of food allergies of unknown origin in the general population may be due to sensitization to *Anisakis* spp., representing a public health issue of growing importance \[[@pone.0203671.ref002],[@pone.0203671.ref003]\]. Moreover, occupational contact was associated with *Anisakis* sensitization and allergic symptoms among fish-processing workers and fishmongers \[[@pone.0203671.ref004],[@pone.0203671.ref005]\].

Humans can become accidental non-permissive hosts of the *Anisakis* parasite by eating parasitized raw or undercooked fish containing larvae in stage 3 \[[@pone.0203671.ref006],[@pone.0203671.ref007]\]. Within hours after being ingested, *Anisakis* larvae penetrate the mucosal layers of the gastrointestinal tract, causing direct tissue damage that may lead to the zoonotic disease known as anisakiasis. This acute gastrointestinal form of *Anisakis* infection is usually transient, with the worm dying within a few weeks. It is manifested by clinical symptoms ranging from nausea, vomiting, diarrhoea, mild to severe abdominal pain and intestinal obstruction \[[@pone.0203671.ref008]\], mimicking other much more common gastrointestinal disturbances, such as acute appendicitis, gastric ulcer, or tumours, thus making diagnosis of anisakiasis extremely difficult.

Moreover, *Anisakis* is implicated in allergic IgE-mediated reactions, occurring after secondary exposure to the parasite, such as urticaria, angioedema, asthma and, rarely, anaphylaxis in highly sensitized people \[[@pone.0203671.ref002], [@pone.0203671.ref009]--[@pone.0203671.ref012]\]. Not by chance, in the past, allergic reactions to *Anisakis* have been mistaken for other entities such as acute urticaria or fish allergy \[[@pone.0203671.ref013]\]. Of interest, high levels of specific IgE for *Anisakis* allergens were also detected in healthy individuals without any clinical symptom.

The current diagnostic algorithm of *Anisakis*-related allergy has been based upon suggestive anamnesis (appearance of symptoms few hours after raw fish intake) along with positive skin prick testing, enzyme-linked immunosorbant assay (ELISA), ImmunoCAP or immunoblotting determination of antigen-specific IgE and exclusion of fish allergy, but the high number of false positives due to cross-reactivities with numerous panallergens has underlined the need to improve the diagnostic approach \[[@pone.0203671.ref014]--[@pone.0203671.ref017]\].

Often, these misdiagnosis lead to a domino cascade of useless diagnostic tests with significant healthcare costs \[[@pone.0203671.ref018]\].

The significant impact of *Anisakis* sensitization in the general population and in specific occupational settings (mainly allergic patients and fishing industry workers) has been stressed by several studies, particularly the ones with the largest sample size, held in Japan, Spain and Italy, documenting how *Anisakis* was a leading cause of food allergies more frequently than seafood itself \[[@pone.0203671.ref004],[@pone.0203671.ref019]--[@pone.0203671.ref021]\]. Furthermore, sensitization to Anisakis was correlated not only with ingestion of contaminated fish, but also among workers whose occupation consisted of frequent handling of raw fish or fishmeal \[[@pone.0203671.ref004]\], also including cooks and restaurant workers \[[@pone.0203671.ref022]--[@pone.0203671.ref025]\].

The accurate assessment of *Anisakis* hypersensitivity prevalence plays a pivotal role to tailor health services and public initiatives according to the needs of the population, particularly in order to plan disease surveillance, ensure sufficient resources to cope with the burden of disease and evaluate trends over time \[[@pone.0203671.ref006]\]. Also, differences in diagnostic techniques and characteristics of populations enrolled led to conflicting reports among various geographical areas \[[@pone.0203671.ref008]\].

We performed a systematic review of the available literature on *Anisakis* sensitization prevalence in general population and other population strata, including occupationally exposed workers, taking into account the impact of the different available diagnostic techniques on the epidemiological data.

Material and methods {#sec002}
====================

Search strategy {#sec003}
---------------

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

Guidelines \[[@pone.0203671.ref026]\] were followed to conduct the systematic review of the literature **([S1 Table](#pone.0203671.s002){ref-type="supplementary-material"}).** Ethics board review was not sought because this review used only publically available information.

### Database search {#sec004}

A systematic review of peer-reviewed English-language literature for *Anisakis* spp. sensitization prevalence data was conducted through a search of Medline and Scopus databases. Initially, free text words representing broad concept of "*Anisakis* allergy" were used to identify the keywords (for example, Medical Subject Headings, MeSH) for subject searching. Then, a combination of MeSH terms and free text words were arranged in the following research string with OR and AND logical operators: *Anisakis AND (prevalence OR epidemiology) AND (allergy OR hypersensitivity OR immunization OR sensitivity OR sensitization OR ELISA OR skin prick test OR ImmunoCAP OR Immunoblot OR diagnostic techniques)*. Reference lists of the articles included in the analysis and of others relevant to the topic were hand-searched to identify additional potentially relevant publications, until no new information was found.

### Other sources {#sec005}

Grey literature was identified by searching for conference or meeting abstracts and proceedings. The literature was last searched on February the 6^th^ 2017.

### Inclusion and exclusion criteria {#sec006}

All articles meeting the following criteria were screened and then assessed for eligibility: peer reviewed manuscripts, published from 1996 to February 2017, reporting *Anisakis* sensitization prevalence estimates, a description of the population involved, the techniques used to test for immunization and the number of people tested.

Reports of analytical studies (cross-sectional studies, prospective or retrospective) were included, with no restriction on age or type of population. Review articles, conference abstracts, editorials and case reports were excluded.

### Screening {#sec007}

After removal of duplicates, the records were screened by two reviewers (CM and DDR) in three levels. The first level included title screening, the second level included abstract screening and the third level included full text screening. For each level, the reviewers separately screened the records. Any disagreement was resolved by consensus with a third author (WM). After screening, studies were assessed for eligibility and final selection.

Study quality assessment process {#sec008}
--------------------------------

Quality assessment of thirty-seven studies included was performed by using an adapted version of the Joanna Briggs Institute Prevalence Critical Appraisal Tool \[[@pone.0203671.ref027]\], which was tailored to the objective and primary outcome measures of this review by modifying in order to account for specific *Anisakis* sensitization test criteria. Each study was assessed for ten criteria (**[Table 1](#pone.0203671.t001){ref-type="table"}**): sample representativeness; participants recruitment; sample size; description of participants and setting; response rate; objective, reliable measurement of *Anisakis* sensitization; reliability of diagnostic techniques; appropriateness of statistical analysis, confounding factors/subgroups/differences identified and accounted for; identification of subpopulations using objective criteria (**[S2 Table](#pone.0203671.s003){ref-type="supplementary-material"}**). Being the maximum score obtainable equal to 14, a score of 7 was considered as cut off between middle-low and middle-high study quality.

10.1371/journal.pone.0203671.t001

###### Criteria for the quality assessment of the studies (adapted from Joanna Briggs Institute Prevalence Critical Appraisal Tool).

![](pone.0203671.t001){#pone.0203671.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------
  Criteria                                                       Score (Maximum score = 14)
  -------------------------------------------------------------- --------------------------------------------------------------------
  **1.** Sample representativeness                               Adequate = 1, Not Adequate = 0, NA

  **2.** Participants recruitment                                Random = 1, all other methods = 0, NA

  **3.** Sample size                                             ≥200 = 1, \<200 = 0, NA

  **4.** Description of participants and setting                 Adequate = 1, Not Adequate = 0, NA

  **5.** Response rate, %                                        \<50% = 0, 50--80% = 1, \>80% = 2

  **6.** Objective, reliable measurement of\                     3 diagnostic criteria (anamnestic, clinical, laboratoristic) = 3;\
  *Anisakis* sensitization                                       only 2 up to 3 criteria = 2; only one criteria = 1

  **7.** Reliability of diagnostic techniques                    Antigens used specified in the text = 2;\
                                                                 only anamnesis = 0, all the other measurement = 1

  **8.** Appropriateness of statistical analysis                 Adequate = 1, Not Adequate = 0, NA

  **9.** Confounding factors/subgroups/differences identified\   Adequate = 1, Not Adequate = 0, NA
  and accounted for                                              

  **10.** Identification of subpopulations using\                Adequate = 1, Not Adequate = 0, NA
  objective criteria                                             
  -----------------------------------------------------------------------------------------------------------------------------------

When only the abstract was available, quality assessment could not be performed.

Data extraction {#sec009}
---------------

Data were extracted using a data extraction MS Excel sheet. Data extraction included authors, year of publication, year of study, study location, study design, statistical measures, study settings, samples size, the characteristics of the studies' participants, as age and females/males ratio, as well as diagnostic techniques and criteria employed to define *Anisakis* sensitization and allergy and relative prevalence estimates. DDR conducted data extraction, while CM performed the analysis of the studies' quality.

Study protocol {#sec010}
--------------

The study protocol has been registered with PROSPERO, number CRD42017057316.

A total of 248 records were identified searching in Medline and Scopus databases.

After title screening, 217 records were excluded. Of the remaining 31 manuscripts, 8 were removed subsequently to abstract evaluation. In the latest phase, full text assessment led to inclusion of all the remaining 23 manuscripts, and 18 more articles fulfilling the inclusion criteria found in the reference lists were added (**[Fig 1](#pone.0203671.g001){ref-type="fig"}**) (**[S1 Database](#pone.0203671.s001){ref-type="supplementary-material"}**).

![Flow diagram for selection of studies on *Anisakis* sensitization prevalence.](pone.0203671.g001){#pone.0203671.g001}

Diagnostic techniques employed {#sec011}
------------------------------

### Skin prick test (SPT) {#sec012}

Sensitization to *Anisakis* is ruled out by the appearance of a \>3 mm diameter wheal on the volar aspect of each subject\'s forearm after scratching the skin in the presence of a dilution of *Anisakis* extract (obtained by the centrifugation of total larvae in phosphate-buffered saline for 15 minutes at 1500 g) \[[@pone.0203671.ref028], [@pone.0203671.ref029]\].

### ImmunoCAP, UniCAP-100, Radio-Allergo-Sorbent Test (RAST) {#sec013}

Total immunoglobulins (Igs), IgE, IgM, IgA1, IgG1, IgG4, antibodies against Anisakis crude extract, excretory-secretory antigens and recombinant antigens Ani s1, Ani s3, Ani s5, Ani s9, and Ani s10 are first detected by incubation with subjects' serum samples and then revealed using an anti-human Igs labelled with radioactive or fluorescent marker \[[@pone.0203671.ref011], [@pone.0203671.ref030]--[@pone.0203671.ref033]\].

### Indirect ELISA {#sec014}

Specific anti-Ani s1 and Ani s7 IgE antibodies are detected in patients' sera after adding diluted *Anisakis* antigens to ELISA plates, and then incubating with secondary antibodies coupled to an enzyme. After washing, so that excess of unbound antibodies can be removed, a substrate is added, and remaining enzymes elicit a chromogenic or fluorescent signal, which is proportional to the antibody-antigen complexes and can be measured as optical density (OD) \[[@pone.0203671.ref034]\].

### Antigen capture ELISA {#sec015}

It is a variation of indirect ELISA in which the serum to be tested is added to wells containing O-deglycosylated *A*. *simplex* antigen bound by the immobilized monoclonal antibody UA3, in order to detect specific IgG1 and IgE \[[@pone.0203671.ref035]\].

### rAni s1, rAni s7 ELISA {#sec016}

Specific anti-Anisakis IgE antibodies are detected by indirect ELISA, with rAni s 7 or rAni s 1 as the target. After incubation of the plates and blocking of nonreactive sites, undiluted serum is added to each well and the specific IgE detected \[[@pone.0203671.ref036]\].

### Immunoblotting {#sec017}

*Anisakis* specific IgE detection is performed by means of sodium dodecylsulfate-polyacrylamide gel electrophoresis with a dilution of *Anisakis* extract or recombinant Ani s1, Ani s3, Ani s5, Ani s9 and Ani s10. Proteins are afterwards transferred to nitrocellulose membranes and incubated overnight with diluted sera from patients in incubation buffer. After washing, the membranes are incubated with appropriate dilution of monoclonal labelled antihuman immunoglobulins \[[@pone.0203671.ref019], [@pone.0203671.ref037]\].

### Basophil activation test (BAT) {#sec018}

Flow-cytometry expression of CD63 on activated basophils is measured on whole blood sample after incubation in a water bath with *Anisakis* crude extract. Samples are lysed, washed and re-suspended to be measured in a flow cytometer after staining cells with 20 μL of CD63-FITC ⁄ CD123-PE ⁄ anti-HLA-DR-PerCP reagent mixture cocktail. Activated basophils were finally identified using anti-CD123, anti-HLA-DR and anti-CD63 monoclonal antibodies \[[@pone.0203671.ref038]\].

Results {#sec019}
=======

The characteristics of the 41 studies reviewed in the qualitative analysis are summarized in **[Table 2](#pone.0203671.t002){ref-type="table"}**.

10.1371/journal.pone.0203671.t002

###### Characteristics of the n. 41 studies included in the systematic review.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                   Country        Study design      Study period   Study setting                                                    Study participants                                                                                    N° of participants                                                                                            Age\                                                                                                               Female n/N\
                                                                                                                                                                                                                                                                                                                                                                      mean (SD) or median (IQR),\                                                                                        (%)
                                                                                                                                                                                                                                                                                                                                                                      range                                                                                                              
  ------------------------------ -------------- ----------------- -------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------
  **Abattouy, 2013**             Morocco        Cross sectional   Not provided   Public clinical analysis laboratories and general practitioner   Inhabitants and fishing industry workers from 2 coastal cities                                        333                                                                                                           38.4\                                                                                                              156/333\
                                                                                                                                                                                                                                                                                                                                                                      22--70                                                                                                             (46.8)

  **Anadon, 2010**               Spain          Cross sectional   1995--2001     Allergy service of Madrid hospital                               Serum samples of Madrid allergic\                                                                     495                                                                                                           44.3\                                                                                                              322/495)\
                                                                                                                                                  inhabitants                                                                                                                                                                                                         5--81                                                                                                              (65)

  **Andreu-Ballester, 2008**     Spain          Case-control      Not provided   1 hospital                                                       Appendectomized patients and non appendectomized patients who presented to the emergency department   160\                                                                                                          39.2 (14)\                                                                                                         76/180\
                                                                                                                                                                                                                                                        (80 appendectomized patients and\                                                                             20--75                                                                                                             (47.5)
                                                                                                                                                                                                                                                        80 non appendectomized patients)                                                                                                                                                                                                 

  **Añíbarro, 2007**             Spain          Cross-sectional   Not provided   1 allergy unit\                                                  Food allergic patients                                                                                436                                                                                                           46 (13.8)\                                                                                                         Not provided
                                                                                 covering 400.000 inhabitants public health area                                                                                                                                                                                                                                      (mean age onset of symptoms)                                                                                       

  **Asero, 2009**                Italy          Cross-sectional   2007           19 allergy outpatient clinics                                    Food allergic patients                                                                                1,110                                                                                                         31\                                                                                                                719/1,110\
                                                                                                                                                                                                                                                                                                                                                                      12--79                                                                                                             (64.7)

  **Bernardini, 2000**           Italy          Cross-sectional   Not provided   1 allergy unit                                                   Children with allergic symptoms                                                                       805                                                                                                           7.9 (3.8)\                                                                                                         324/805\
                                                                                                                                                                                                                                                                                                                                                                      0.52±17.61                                                                                                         (40.2)

  **Caballero,**\                Spain          Cross-sectional   Not provided   1 allergy unit                                                   Tolerant patients with suspected not-fish-related allergy and\                                        99\                                                                                                           36.2\                                                                                                              Not provided
  **2012**                                                                                                                                        patients with allergy to *A*. *simplex*.                                                              (tolerant patients with suspected not-fish-related allergy)\                                                  (tolerant patients with suspected not-fish-related allergy)\                                                       
                                                                                                                                                                                                                                                        35\                                                                                                           52.5\                                                                                                              
                                                                                                                                                                                                                                                        (patients with allergy to *A*. *simplex)*                                                                     (patients with allergy to A. simplex).                                                                             

  **Consortium AAITO-IFIACI**\   Italy          Cross-sectional   2010           34 allergy units                                                 Suspected allergy patients                                                                            10,570                                                                                                        Not provided                                                                                                       Not provided
  **Anisakis, 2010**                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Daschner, 2005**             Spain          Cross-sectional   Not provided   1 allergy unit                                                   Chronic urticaria patients                                                                            135                                                                                                           41.5 (15.4)                                                                                                        91/135\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         (67.4)

  **del Pozo, 1997**             Spain          Cross-sectional   Not provided   1 allergy unit                                                   Urticaria/angioedema patients                                                                         100                                                                                                           37.4\                                                                                                              63/100\
                                                                                                                                                                                                                                                                                                                                                                      18--75                                                                                                             (63.0)

  **Del Rey Moreno, 2006**       Spain          Cross-sectional   2000           1 hospital laboratory                                            Random healthy blood donors                                                                           77                                                                                                            Not provided                                                                                                       Not provided

  **Estrada Rodriguez, 1997**    Spain          Cross-sectional   Not provided   1 hospital laboratory                                            Not provided                                                                                          66                                                                                                            Not provided                                                                                                       Not provided

  **Falcao, 2008**               Portugal       Case-control      Not provided   Immuno-\                                                         Cases with of acute urticaria\                                                                        200 (cases with of acute urticarial).\                                                                        6--18                                                                                                              66/200\
                                                                                 allergology and surgery units of the largest paediatric\         Controls among programmed surgery patients                                                            200 (controls among programmed surgery patients).\                                                                                                                                                                               (33.0)\
                                                                                 hospital in Porto                                                                                                                                                      400 overall                                                                                                                                                                                                                      for cases.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         92/200\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         (46.0)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         for controls.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Overall 158/400\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         (39.5)

  **Figueiredo, 2013**           Brazil         Cross-sectional   2010           1 military facility                                              Healthy adult affiliated with a military facility                                                     67                                                                                                            40 ± 8.4 years (median)                                                                                            Not provided

  **Figueiredo, 2015**           Brazil         Cross-sectional   2009--2010     2 perinatal centers\                                             Mother-newborn pairs                                                                                  139 from LRBU\                                                                                                24.80 (LRBU)\                                                                                                      309/309\
                                                                                 (1 high-risk birth unit\                                                                                                                                               170 from HRBU\                                                                                                26.19 (HRBU)\                                                                                                      (100)
                                                                                 and 1low-risk birth unit)                                                                                                                                              309 overall                                                                                                   overall range\                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                      15--42                                                                                                             

  **Frezzolini, 2010**           Italy          Case-control      Not provided   Laboratory of immunology and allergology unit                    Chronic urticaria patients, atopic patients, healthy controls                                         57 chronic urticaria patients, 22 atopic patients, 20\                                                        Chronic urticaria patients:\                                                                                       Chronic urticaria patients: 49/57 (86.0)\
                                                                                                                                                                                                                                                        healthy controls                                                                                              42 (11)\                                                                                                           Not provided for controls
                                                                                                                                                                                                                                                                                                                                                                      24--54\                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                      Not provided for controls                                                                                          

  **Garcia, 1997**               Spain          Case-control      Not provided   1 hospital                                                       Cases: patients with urticaria, angioedema, or anaphylaxis;\                                          61 cases,\                                                                                                    47\                                                                                                                39/61\
                                                                                                                                                  controls: healthy blood donors                                                                        51 controls                                                                                                   21--72\                                                                                                            (63.9)\
                                                                                                                                                                                                                                                                                                                                                                      for cases,\                                                                                                        for cases,\
                                                                                                                                                                                                                                                                                                                                                                      41\                                                                                                                22/47\
                                                                                                                                                                                                                                                                                                                                                                      18--65 for controls                                                                                                (46.8) for controls

  **García-Palacios, 1996**      Spain          Cross-Sectional   Not provided   1 hospital laboratory                                            Randomly selected adults showing no clinical suspicion of anisakidosis                                1,008                                                                                                         Not provided                                                                                                       Not provided

  **Garcia-Perez, 2015**         Spain          Case-control      2010--2013     1 hospital                                                       gastric cancer patients, healthy controls                                                             47 cases, 47 controls                                                                                         70\                                                                                                                24/47\
                                                                                                                                                                                                                                                                                                                                                                      (48--92)\                                                                                                          (51.1)\
                                                                                                                                                                                                                                                                                                                                                                      for cases,\                                                                                                        for cases,\
                                                                                                                                                                                                                                                                                                                                                                      65\                                                                                                                21/47\
                                                                                                                                                                                                                                                                                                                                                                      (46--83) for controls                                                                                              (44.7) for controls

  **Gomez, 1998**                Spain          Case-control      1989--1996     1 allergy unit                                                   Cases with eosiniphilic gastroenteritis,\                                                             10 cases, 149 controls without digestive disorder, 10 controls with\                                          50 for cases, not provided for controls                                                                            4/10\
                                                                                                                                                  controls without digestive disorder,\                                                                 digestive disorder different from eosinophilic gastroenteritis                                                                                                                                                                   (40.0) for cases, not provided for controls
                                                                                                                                                  controls with\                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                  digestive disorder different from eosinophilic gastroenteritis                                                                                                                                                                                                                                                                         

  **González de Olano, 2007**    Spain          Cross-sectional   2003--2005     1 Allergy unit                                                   adults with mastocytosis, children with mastocytosis,\                                                163 adults with mastocytosis, 47 children with mastocytosis, 50 controls                                      43 (median)\                                                                                                       88/163\
                                                                                                                                                  controls                                                                                                                                                                                                            (18--75)\                                                                                                          (54.0)\
                                                                                                                                                                                                                                                                                                                                                                      for adults with mastocytosis8 (median)\                                                                            for adults with mastocytosis\
                                                                                                                                                                                                                                                                                                                                                                      (0.6--14) for children with mastocytosis,\                                                                         17/47\
                                                                                                                                                                                                                                                                                                                                                                      Range 2--70 for controls                                                                                           (36.2) for children with mastocytosis, not provided for controls

  **Gonzalez Munoz, 2005**       Spain          Cross-sectional   Not\           1 Department of Immunology                                       consecutive patients\                                                                                 88 overall (37 *Anisakis* sensitized, 51 with chronic urticaria/abdominal pain unrelated to fish ingestion)   median 34\                                                                                                         60/88\
                                                                  provided                                                                        divided into *Anisakis* sensitized (symptoms + IgE+),\                                                                                                                                                              (IQR = 28--48)                                                                                                     (68.2)
                                                                                                                                                  chronic urticaria/abdominal pain unrelated to fish ingestion                                                                                                                                                                                                                                                                           

  **Guillén-Bueno, 1999**        Spain          Cross-sectional   Not\           1 hospital (gastroenterology Service)                            Crohn's disease patients, random controls                                                             73 cases, 251 controls                                                                                        35.1 (12.2)\                                                                                                       42/73\
                                                                  provided                                                                                                                                                                                                                                                                                            15--73                                                                                                             (57.5)

  **Gutierrez, 2002**            Spain          Cross-sectional   1996--1997     1 hospital (gastroenterology Service)                            Gastrointestinal diseases patients,\                                                                  57 gastrointestinal diseases patients, 19 patients with digestive\                                            42.4 (17.6) gastrointestinal diseases patients, 54.3 (15.9)\                                                       Not provided
                                                                                                                                                  patients with digestive\                                                                              haemorrhaging,\                                                                                               patients with digestive\                                                                                           
                                                                                                                                                  haemorrhaging,\                                                                                       30 patients with Crohn's disease,\                                                                            haemorrhaging, 37.2 (11.5)\                                                                                        
                                                                                                                                                  patients with Crohn's disease,\                                                                       4 patients with digestive cancer\                                                                             patients with Crohn's disease, 71.3 (5.7) patients with digestive cancer, 24.8 (4.7) patients with appendicitis.   
                                                                                                                                                  patients with digestive cancer, patients with appendicitis.                                           5 patients with appendicitis.                                                                                                                                                                                                    

  **Heffler, 2016**              Italy          Cross-sectional   2010--2012     1 Allergy unit                                                   Consecutive allergic patients                                                                         3,419                                                                                                         34.3\                                                                                                              2,114/3,419\
                                                                                                                                                                                                                                                                                                                                                                      3--88                                                                                                              (61.8)

  **Kim, 2011**                  South Korea    Cross-sectional   Not\           3 hospitals laboratories                                         Non allergic patients admitted for health examinations                                                498                                                                                                           from teens to 98                                                                                                   269/498\
                                                                  provided                                                                                                                                                                                                                                                                                                                                                                                                               (54.0)

  **Kimura, 1999**               Japan          Cross-sectional   1994--1997     Various laboratories throughout Japan                            Allergic patients                                                                                     2,108                                                                                                         Not\                                                                                                               Not\
                                                                                                                                                                                                                                                                                                                                                                      provided                                                                                                           provided

  **Lin, 2012**                  Norway         Cross-sectional   Not\           1 university hospital,\                                          blood donors,\                                                                                        100 blood donors, 798\                                                                                        Not\                                                                                                               Not\
                                                                  provided       allergy laboratory                                               suspected allergy patients                                                                            suspected allergy patients                                                                                    provided                                                                                                           provided

  **Lin, 2014**                                 Cross-sectional   Not\           1 university hospital,\                                          Blood donors,\                                                                                        993 blood donors, 414\                                                                                        Not\                                                                                                               Not\
                                                                  provided       allergy laboratory                                               patient with total IgE levels ≥1000 kU/L                                                              patient with total IgE levels ≥1000 kU/l                                                                      provided                                                                                                           provided

  **Mazzucco,**\                 Italy          Cross-sectional   2009           1 hospital laboratory                                            Fishing industry workers                                                                              94                                                                                                            42.1 (12)                                                                                                          16/94\
  **2012**                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (17.0)

  **Mladineo, 2014**             Croatia        Cross-sectional   2010--2011     1 county\                                                        Unpaid randomly selected volunteer healthy subjects                                                   500                                                                                                           58.1                                                                                                               242\
                                                                                 secondary healthcare provider Medicine-biochemical Laboratory                                                                                                                                                                                                                                                                                                                                           (48.4)

  **Montoro, 1997**              Spain          Cross-sectional   1995           1 hospital immunology and allergy service                        Acute recidivous urticaria patients who usually eat fish or other seafood                             25                                                                                                            39.3 (19.8)\                                                                                                       16/25\
                                                                                                                                                                                                                                                                                                                                                                      11--77                                                                                                             (64.0)

  **Nieuwenhuizen,2006**         South Africa   Cross-sectional   Not\           1 laboratory                                                     Fishing industry workers                                                                              578                                                                                                           Not\                                                                                                               Not\
                                                                  provided                                                                                                                                                                                                                                                                                            provided                                                                                                           provided

  **Pascual, 1996**              Spain          Cross-sectional   Not\           1 laboratory                                                     Patients with\                                                                                        73                                                                                                            Not\                                                                                                               Not\
                                                                  provided                                                                        increased levels of serum total IgE                                                                                                                                                                                 provided                                                                                                           provided

  **Puente, 2008**               Spain          Cross-sectional   Not\           1 laboratory                                                     Allergic residents\                                                                                   86 allergic residents\                                                                                        Not provided\                                                                                                      Not\
                                                                  provided                                                                        of Madrid, non-allergic subjects divided in patients with non-digestive non-allergic\                 of Madrid,\                                                                                                   for allergic residents\                                                                                            provided
                                                                                                                                                  pathologies unrelated to anisakiosis and\                                                             314 non-allergic subjects divided in\                                                                         of Madrid;\                                                                                                        
                                                                                                                                                  healthy residents of Madrid                                                                           50 patients with non-digestive non-allergic\                                                                  57.6 (20--85) for patients with non-digestive non-allergic\                                                        
                                                                                                                                                                                                                                                        pathologies unrelated to anisakiosis, and 264 healthy residents of\                                           pathologies unrelated to anisakiosis,\                                                                             
                                                                                                                                                                                                                                                        Madrid                                                                                                        32.9 (18--65) for healthy residents of\                                                                            
                                                                                                                                                                                                                                                                                                                                                                      Madrid                                                                                                             

  **Purello-D'Ambrosio, 2000**   Italy          Cross-sectional   Not\           1 Laboratory                                                     males in daily contact with fish,\                                                                    28 males in daily contact with fish, 15 non atopic healthy males                                              30.6\                                                                                                              0\
                                                                  provided                                                                        non atopic healthy males                                                                                                                                                                                            (18--48) for males in daily contact with fish, 32.5 (20--44) for non atopic healthy males                          (0.0%)

  **Rodriguez, 2000**            Spain          Cross-sectional   Not\           1 allergology clinic                                             Drug allergy patients                                                                                 53                                                                                                            48.0 (16.7)\                                                                                                       36/53\
                                                                  provided                                                                                                                                                                                                                                                                                            17--75                                                                                                             (67.9)

  **Toro, 2004**                 Spain          Cross-sectional   1998           1 hospital                                                       Dyspeptic patients                                                                                    174                                                                                                           49.3 (15.1)\                                                                                                       83/173\
                                                                                                                                                                                                                                                                                                                                                                      21--80                                                                                                             (48.0)

  **Uga, 1996**                  Indonesia      Cross-sectional   1992--1993     1 hospital                                                       Hospital visitors for diarrhea or routine check-ups                                                   244                                                                                                           35\                                                                                                                120/244\
                                                                                                                                                                                                                                                                                                                                                                      1--80                                                                                                              (49.2)

  **Valinas, 2001**              Spain          Cross-sectional   Not\           1 laboratory                                                     Normal unpaid volunteer healthy blood donors                                                          2,801                                                                                                         Not\                                                                                                               Not\
                                                                  provided                                                                                                                                                                                                                                                                                            provided                                                                                                           provided

  **Ventura, 2013**              Italy          Cross-sectional   Not\           1 allergology unit                                               Adult allergic patients                                                                               919                                                                                                           17--83                                                                                                             622/919\
                                                                  provided                                                                                                                                                                                                                                                                                                                                                                                                               (67.7)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Thirty-four studies followed a cross-sectional design, while the remaining ones (n = 7) were designed as case-control study. Twenty-two studies were made on symptomatic allergic population and among them only one specifically enrolled children (Bernardini, 2000) \[[@pone.0203671.ref039]\]. Three studies included only occupationally exposed population working in the fishing industry (Purello-D'Ambrosio 2000 \[[@pone.0203671.ref040]\], Nieuwenhuizen N 2006 \[[@pone.0203671.ref005]\], Mazzucco 2012 \[[@pone.0203671.ref004]\]), while Abattouy 2013 \[[@pone.0203671.ref041]\] included both inhabitants and fish workers from two coastal cities in Morocco.

Quality scores ranged from a minimum of 5 (Kimura, 1999) \[[@pone.0203671.ref020]\] to a maximum of 13 (Anadon 2010 \[[@pone.0203671.ref036]\], Mladineo, 2014 \[[@pone.0203671.ref042]\]) up to 14 points scale. Thirty-eight studies were considered of medium-high quality being rated 7 or more, including five studies scoring 10 and three studies scoring 11. Four studies were excluded from quality assessment since only respective abstracts were available (Estrada Rodriguez 1997 \[[@pone.0203671.ref043]\], Pascual 1996 \[[@pone.0203671.ref044]\], Rodriguez 2000 \[[@pone.0203671.ref045]\], Uga 1996 \[[@pone.0203671.ref046]\]). Extended evaluations on each items analysed for the critical appraisal are in **[S2 Table](#pone.0203671.s003){ref-type="supplementary-material"}**.

Data on prevalence, according to different study samples and the diagnostic tests applied, are shown in **[Table 3](#pone.0203671.t003){ref-type="table"}**.

10.1371/journal.pone.0203671.t003

###### Prevalence of *Anisakis* sensitization according to different study samples and diagnostic tests.

![](pone.0203671.t003){#pone.0203671.t003g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year, (reference)                                                         Sample characteristics                                                                                                                                                                                                                                   Sample size (n)\                                                                                            Skin Prick Tests\                                                                                                     ELISA/ImmunoCAP\                                                                                                         Other tests / criteria
                                                                                                                                                                                                                                                                                                                                             age range (mean, SD)                                                                                        % (n), \>*3 mm threshold*                                                                                             % (n), *threshold*                                                                                                       
  --------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **General asymptomatic population (15 studies)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Abattouy, 2013                                                                    Random samples                                                                                                                                                                                                                                           **333**                                                                                                     **-**                                                                                                                 **5.1%**                                                                                                                 **-**

  Del Rey Moreno, 2006                                                              Healthy blood donors                                                                                                                                                                                                                                     **77**                                                                                                      **-**                                                                                                                 **22.1%**\                                                                                                               Immunoblot\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (n = 17)                                                                                                                 **67.5%**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        recognized antigens of *A*. *simplex*

  Figueiredo, 2013                                                                  Healthy military                                                                                                                                                                                                                                         **67**                                                                                                      **-**                                                                                                                 **20.9%**\                                                                                                               **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (n = 14)                                                                                                                 

  Frezzolini, 2010                                                                  Healthy subjects                                                                                                                                                                                                                                         **20**                                                                                                      **10.0%**                                                                                                             **10.0%**                                                                                                                **0.0%** CD63 BAT

  Garcia, 1997                                                                      Healthy blood donors                                                                                                                                                                                                                                     **51**                                                                                                      **19.6%**\                                                                                                            **27.4%**                                                                                                                Immunoblot [^**1**^](#t003fn001){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                                         (n = 10)                                                                                                                                                                                                                                       **75.0%** type 4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **1.9%** (n = 1) type 1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **15.0%** type 3

  García-Palacios, 1996                                                             Random sera                                                                                                                                                                                                                                              **1,008**                                                                                                   **-**                                                                                                                 **6.0%**\                                                                                                                **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (n = 61)                                                                                                                 

  Garcia-Perez, 2015                                                                Healthy controls                                                                                                                                                                                                                                         **47**                                                                                                      **-**                                                                                                                 **6.4%** IgA1, rAni s 1; **10.6%** IgA1, rAni s 5                                                                        **-**

  Guillén-Bueno, 1999                                                               Asymptomatic adults                                                                                                                                                                                                                                      **251**                                                                                                     **-**                                                                                                                 **18.3%**                                                                                                                Immunoblot\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        E17, 50-70-250 kDa eosinophilia, leukocytosis

  Lin, 2012                                                                         Blood donors                                                                                                                                                                                                                                             **100**                                                                                                     **-**                                                                                                                 **2.0%** ImmunoCAP \> 0.35 kU/L                                                                                          **-**

  Lin, 2014                                                                         Blood donors                                                                                                                                                                                                                                             **993**                                                                                                     **-**                                                                                                                 **0.4%** ImmunoCAP\                                                                                                      Immunoblot 40--100 kDa\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (**0.0%** ELISA with rAni s 1 and rAni s 7)                                                                              (weaker bands)

  Mladineo, 2014                                                                    Random healthy                                                                                                                                                                                                                                           **500**                                                                                                     **-**                                                                                                                 **2.0%** indirect ELISA\                                                                                                 **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Ani s 1 s 7                                                                                                              

  Puente, 2008                                                                      Healthy residents                                                                                                                                                                                                                                        **264** (18--65 years)                                                                                      **-**                                                                                                                 **11.7%** UA3 Ani s 7                                                                                                    **-**

  Purello-D'Ambrosio, 2000                                                          Healthy donors not occupationally exposed                                                                                                                                                                                                                **15**                                                                                                      **6.6%** (n = 1)                                                                                                      **0.0%** (n = 0) RAST                                                                                                    **-**

  Valinas, 2001                                                                     Healthy blood donors                                                                                                                                                                                                                                     **2,801**                                                                                                   **-**                                                                                                                 **0.4%** UA3                                                                                                             **-**

  Ventura, 2013                                                                     Healthy controls                                                                                                                                                                                                                                         **187**                                                                                                     **16.0%**                                                                                                             **-**                                                                                                                    **-**

  **Occupationally exposed population, symptomatic and asymptomatic (3 studies)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Mazzucco, 2012                                                                    94 workers in fisheries sector: fishmongers (n = 21), fish industry emplooyees (n = 35), Fishermen/sailors (n = 38)                                                                                                                                      **94**                                                                                                      **-**                                                                                                                 **11.7%**\                                                                                                               **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (n = 11)\                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               UniCAP-100                                                                                                               

  Nieuwenhuizen, 2006                                                               workers employed in 2 large fish-processing workplaces in the Western Cape province of South Africa                                                                                                                                                      **578**                                                                                                     **8.0%**\                                                                                                             **-**                                                                                                                    **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                         (n = 46)                                                                                                                                                                                                                                       

  Purello-D'Ambrosio, 2000                                                          Fishermen/fishmongers occupationally exposed group                                                                                                                                                                                                       **28**                                                                                                      **46.4%**\                                                                                                            RAST\                                                                                                                    **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                         **(**n = 13)                                                                                                          **50.0%**\                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (n = 14)                                                                                                                 

  **Symptomatic population with allergies to any kind of allergen (24 studies)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Anadon, 2010                                                                      Food allergic;\                                                                                                                                                                                                                                          **493** food allergic;\                                                                                     **-**                                                                                                                 CAP-FEIA: **52.7%**\                                                                                                     **-**
                                                                                    controls non food-related allergic                                                                                                                                                                                                                       **25** controls non food-related allergic.                                                                                                                                                                                        (n = 195 true positive\                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               + 65 false positive)\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3 false negative;\                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ELISA rAni s 1 s 7:\                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **40.2%** (n = 198)\                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0 false positive\                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0 false negative                                                                                                         

  Añíbarro, 2007                                                                    Food allergic                                                                                                                                                                                                                                            **436**                                                                                                     **12.4%** [^**2**^](#t003fn002){ref-type="table-fn"}                                                                  **12.4%** [^**2**^](#t003fn002){ref-type="table-fn"}                                                                     **-**

  Asero, 2009                                                                       Food allergic                                                                                                                                                                                                                                            **1,110** (12--79 years)                                                                                    **-**                                                                                                                 **-**                                                                                                                    **0.3%** prevalence of systemic reactions/ anaphylaxis

  Bernardini, 2000                                                                  Suspect allergy                                                                                                                                                                                                                                          **805** (0.5--17.6 years)                                                                                   **6.1%** (n = 49)                                                                                                     **-**                                                                                                                    **-**

  Caballero, 2012                                                                   **Sample A**: suspect allergy other than fish related; **sample B**: *Anisakis* allergic patients (anaphylaxis, angioedema, urticaria or gastrointestinal symptoms few hours after eating undercooked fish)                                              Sample A: **99;** sample B: **35**                                                                          Sample A: **18.0%;** sample B: **100%**                                                                               ImmunoCAP: sample A: **17.0%**; sample B: **100%**                                                                       Immunoblot rAni s 1,3,5,9,10: sample A: **15.0%**; sample B: **100%**

  Consortium AAITO-IFIACI\                                                          Suspect allergy                                                                                                                                                                                                                                          **10,570**                                                                                                  **4.5%** (n = 474)                                                                                                    **-**                                                                                                                    Anamnesis + exclusion fish allergy: **0.6%** overall; **14.0%** of sensitized
  *Anisakis*, 2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Daschner, 2005                                                                    Chronic urticaria                                                                                                                                                                                                                                        **135**                                                                                                     **48.1%** (combined SPT+ and IgE+)                                                                                    **52.6%** (only IgE+)\                                                                                                   **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **31.8%** (only IgG4)                                                                                                    

  Del Pozo, 1997                                                                    Urticaria/angioedema (AE) or anaphylaxis                                                                                                                                                                                                                 **100**                                                                                                     **14.0%**                                                                                                             **22.0%** *(\>0*.*7 kU/L)*                                                                                               \+ symptoms \< 6 h after fish ingestion + exclusion other causes: 8.0%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        real allergy to *Anisakis*

  Estrada Rodriguez, 1997                                                           Asthmatic/urticaria                                                                                                                                                                                                                                      **66**                                                                                                      **-**                                                                                                                 **19.7%** (n = 13)                                                                                                       **-**

  Falcao, 2008                                                                      Relapsing acute urticaria                                                                                                                                                                                                                                **200**                                                                                                     **16.5%**                                                                                                             **6.0%** *(\>0*.*7 kU/L IgE);* **9.0%** *(\>0*.*35 kU/L IgE)*                                                            Combinations SPT IgE: **2.5%** *(SPT and \>0*.*7 IgE);*\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **3.0%** *(SPT and \>0*.*35 IgE);*\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **20.0%** *(SPT or\> 0*.*7 IgE);*\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **22.5%** *(SPT or \>0*.*35 IgE)*

  Frezzolini, 2010                                                                  Chronic urticarial,\                                                                                                                                                                                                                                     **57** chronic urticarial; **22** atopic patients                                                           **63.0%** chronic urticarial; **14.0%** atopic patients                                                               **61.0%** *(\> 0*.*35 kU/L)*\                                                                                            CD63 BAT **67.0%**\
                                                                                    atopic patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                            chronic urticarial; **18.0%** atopic patients                                                                            combined **75%**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        chronic urticarial;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **0.0%** atopic patients

  Garcia, 1997                                                                      Subjects with IgE against *Anisakis* divided into: **allergic**\                                                                                                                                                                                         **61** overall (**25** allergic; **16** non allergic; **20** doubtful)                                      **92.0%** allergic;\                                                                                                  CAP-radioimmunoassay\                                                                                                    Immunoblot ^1^: allergic: **80.0%** type 1 pattern,\
                                                                                    (anamnesis, the time interval \<4 hours between the ingestion of fish and the onset of the reaction, and the exclusion of other causes of allergy); **non allergic** (had not eaten any fish 12 hours before the onset of the symptoms); **doubtful**\                                                                                                               **50.0%** non allergic; **70.0%** doubtful                                                                            100% [^3^](#t003fn003){ref-type="table-fn"} overall;\                                                                    **8.0%** type 3; non allergic: **12.5%** (n = 2) type 1,\
                                                                                    (who did not remember the previous ingestion of fish or for whom the interval between ingestion and onset of symptoms was between 4 and 12 hours)                                                                                                                                                                                                                                                                                                                                          **100%** [^3^](#t003fn003){ref-type="table-fn"} allergic;\                                                               **56.3%** (n = 9) type 4, **19.0%** type 3; doubtful: **40.0%** type 1, **35.0%** type 3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **100%** [^3^](#t003fn003){ref-type="table-fn"} non allergic; **100%** [^3^](#t003fn003){ref-type="table-fn"} doubtful   

  Gomez, 1998                                                                       Suspected allergy                                                                                                                                                                                                                                        **147**                                                                                                     **10.0%** [^**2**^](#t003fn002){ref-type="table-fn"}                                                                  **10.0%** [^**2**^](#t003fn002){ref-type="table-fn"}                                                                     **-**

  González de Olano, 2007                                                           Mastocytosis: adults (18--65 years); children\                                                                                                                                                                                                           **163** adults; **47** children                                                                             **-**                                                                                                                 **26.9%** (n = 44) adults; **0.0%** (n = 0) children                                                                     symptoms referred\
                                                                                    (7 months-14 years)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **13.6%** (n = 6) adults; **0.0%** (n = 0) children

  Gonzalez Munoz, 2005                                                              Suspect allergy\                                                                                                                                                                                                                                         **88** overall; **37** *Anisakis* allergy;\                                                                 **-**                                                                                                                 **42.0%** (n = 37)\                                                                                                      CD63 BAT\
                                                                                    subdivided into:\                                                                                                                                                                                                                                        **51** chronic urticaria or\                                                                                                                                                                                                      had a clinical history of *A*. *simplex* allergy confirmed by IgE+                                                       *Anisakis*+ vs *Anisakis*- and *Anisakis* + vs\
                                                                                    *Anisakis* allergy;\                                                                                                                                                                                                                                     abdominal pain unrelated to fish ingestion; **12** healthy controls                                                                                                                                                                                                                                                                                        healthy controls, the cutoff for a positive basophil activation test was 21% (specificity = 96%, sensitivity =\
                                                                                    chronic urticaria or\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               100%), and 16% (sensitivity and specificity of 100%) respectively
                                                                                    abdominal pain unrelated to fish ingestion; healthy controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Heffler, 2016                                                                     Allergic clinic outpatients                                                                                                                                                                                                                              **3,419**                                                                                                   **15.0%**                                                                                                             **-**                                                                                                                    **0.8%** + allergic symptoms after raw fish

  Kimura, 1999                                                                      Urticaria or food allergy                                                                                                                                                                                                                                **2,108**                                                                                                   **-**                                                                                                                 **29.8**% (n = 629) *(\>0*.*7 kU/L IgE)*                                                                                 **-**

  Lin, 2012                                                                         Serum samples from\                                                                                                                                                                                                                                      **600** sample A; **198** sample B                                                                          **-**                                                                                                                 ImmunoCAP *(\> 0*.*35 kU/L);* **2.2%** sample A; **6.6%** sample B                                                       **-**
                                                                                    Allergy laboratory: **sample A** without any\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                    additional information on analytical results; **sample B** Phadiatop+ subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Lin, 2014                                                                         Subjects with total IgE levels ≥1000 kU/L                                                                                                                                                                                                                **414**                                                                                                     **-**                                                                                                                 **16.2%** (**0.2%** ELISA with rAni s 1 and rAni s 7)                                                                    Immunoblot\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        five bands ranging between 40 and 100 kDa to *A*. *simplex* CE

  Montoro, 1997                                                                     Patients with acute recidivous urticaria who usually eat fish or other seafood.                                                                                                                                                                          **25**                                                                                                      **64.0%** (n = 16)                                                                                                    **76.0%** (n = 19)                                                                                                       Immunoblot\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **56.0%** (14 of the 25) tested sera showed the characteristic band at 49.8--80 kDa compared to the E17 reference serum. Most of the sera showed a common immunorecognition pattern with a group of bands at 200--80 kDa

  Pascual, 1996                                                                     Patients with\                                                                                                                                                                                                                                           **73** overall; **16** shellfish allergy; **20** fish allergy; **17** probable parasitic disease; **20**\   **-**                                                                                                                 **56.2%** (n = 41) overall; **81.3%** shellfish allergy;\                                                                **-**
                                                                                    increased levels of\                                                                                                                                                                                                                                     respiratory allergy                                                                                                                                                                                                               **40.0%** fish allergy;\                                                                                                 
                                                                                    serum total IgE divided into: shellfish allergy; fish allergy; probable parasitic disease;\                                                                                                                                                                                                                                                                                                                                                                                                **58.8%** probable parasitic disease;\                                                                                   
                                                                                    respiratory allergy                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **50.0%** respiratory allergy                                                                                            

  Puente, 2008                                                                      Allergic residents with negative skin prick test to *Anisakis*                                                                                                                                                                                           **86**                                                                                                      **0.0%** [^3^](#t003fn003){ref-type="table-fn"}                                                                       **3.5%** UA3 Ani s 7                                                                                                     **-**

  Rodriguez, 2000                                                                   Drug allergic patients                                                                                                                                                                                                                                   **53**                                                                                                      **54.7%** (n = 29)                                                                                                    **-**                                                                                                                    **-**

  Ventura, 2013                                                                     Chronic urticaria                                                                                                                                                                                                                                        **213**                                                                                                     **49.7%**                                                                                                             **-**                                                                                                                    **-**

  **Hospital presenting patients for any reason (5 studies)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Andreu-Ballester, 2008                                                            Non appendectomized controls presenting at emergency department                                                                                                                                                                                          **80**                                                                                                      **-**                                                                                                                 **1.3%** IgG+; **7.5%** IgM+; **3.8%** IgA+;\                                                                            **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **5.0%** IgE+                                                                                                            

  Falcao, 2008                                                                      Controls selected for\                                                                                                                                                                                                                                   **200** (6--18 years)                                                                                       **5.5%**                                                                                                              **1.5%** *(\>0*.*7 kU/L IgE);* **3.0%** *(\>0*.*35 kU/L IgE)*                                                            Combinations SPT ± IgE: **0.5%** *(SPT+ and \>0*.*7 kU/L IgE);* **1.5%** *(SPT+ and \>0*.*35 kU/L IgE);* **6.5%** *(SPT+ or \> 0*.*7 kU/L IgE);* **7.0%** *(SPT or \>0*.*35 kU/L IgE)*
                                                                                    programmed orthopaedic, maxillofacial, or general surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Kim 2011                                                                          Subjects presenting at hospital for routine controls                                                                                                                                                                                                     **498**                                                                                                     **-**                                                                                                                 **5.0%** larval *Anisakis* crude extract; **6.6%**\                                                                      Immunoblot\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *excretory-secretory proteins*                                                                                           A specific protein band of 130 kDa was detected from 10 patients with western blot analysis against crude extract and excretory-secretory proteins among those who showed positive results by ELISA

  Puente, 2008                                                                      Non-digestive nonallergic\                                                                                                                                                                                                                               **50**                                                                                                      **-**                                                                                                                 **16.0%** UA3 Ani s 7                                                                                                    \-
                                                                                    pathologies unrelated to anisakiosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Uga, 1996                                                                         Diarrhea /routine check-up without symptoms                                                                                                                                                                                                              **244**                                                                                                     **-**                                                                                                                 **11.0%**                                                                                                                **-**

  **Patients with digestive system disorders (6 studies)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Andreu-Ballester,2008                                                             Cases appendectomized                                                                                                                                                                                                                                    **80**                                                                                                      **-**                                                                                                                 **2.5%** IgG+; **2.5%** IgM+; **1.3%** IgA+;\                                                                            **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **2.5%** IgE+;                                                                                                           

  Garcia-Perez, 2015                                                                Cases gastrointestinal cancer                                                                                                                                                                                                                            **47**                                                                                                      **-**                                                                                                                 **38.3%** IgA1+, rAni s 1, **42.6%** IgA1+, rAni s 5                                                                     **-**

  Gomez, 1998                                                                       **Sample A**: eosinophilic gastroenteritis; **sample B**: digestive disorder different from eosinophilic gastroenteritis                                                                                                                                 Sample A: **10**; Sample B: **10**                                                                          Sample A: **80.0%**[^3^](#t003fn003){ref-type="table-fn"} Sample B: **10.0%**[^3^](#t003fn003){ref-type="table-fn"}   Sample A: **80.0%**[^3^](#t003fn003){ref-type="table-fn"}; Sample B: **10.0%**[^3^](#t003fn003){ref-type="table-fn"}     **-**

  Guillen Bueno, 1999                                                               Crohn disease                                                                                                                                                                                                                                            **73**                                                                                                      **-**                                                                                                                 **29.0%** specific total Ig (G+M+A)\                                                                                     Immunoblot:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **44.0%** IgG+;\                                                                                                         *human anisakidosis reference serum (E17); 50 and 250 kDa*, *with a band of about 70 kDa*
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **18.0%** IgM+;\                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **53.0%** IgA+                                                                                                           

  Gutierrez, 2002                                                                   19 digestive\                                                                                                                                                                                                                                            **57** (42.38 ± 17.60 years)                                                                                **-**                                                                                                                 **Crude Extract:**\                                                                                                      Immunoblot\
                                                                                    Haemorrhaging;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Igs-CE **89.4%**;\                                                                                                       **24.0%** *and* **48.0%** *of sera from patients with symptoms of Crohn's disease and digestive haemorrhaging*, *respectively*, *showed a positive immunorecognition pattern of CE antigen*.
                                                                                    30 Crohn's disease;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                       IgG-CE **75.4%**;\                                                                                                       
                                                                                    4 digestive cancer;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                       IgM- CE **26.3%**;\                                                                                                      
                                                                                    5 appendicitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                             IgA- CE **63.1%**;\                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               IgE- CE **14.0%**;\                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Excretory- Secretory antigens:**\                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Igs- ES **49.1%**;\                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               IgG- ES **57.8%**;\                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               IgM- ES **22.8%**;\                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               IgA- ES **57.8%**                                                                                                        

  Toro, 2004                                                                        Dyspeptic symptoms                                                                                                                                                                                                                                       **174**                                                                                                     **-**                                                                                                                 **13.8%** (n = 24)\                                                                                                      **-**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               IgE anti Ani s 1                                                                                                         

  **Post-partum women (1 study)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Figueiredo, 2015                                                                  170 from high-risk birth unit and 139 from a low-risk birth unit                                                                                                                                                                                         **309**                                                                                                     **-**                                                                                                                 **19.4%** (n = 60) IgG+                                                                                                  **-**
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ Pattern types: type 1: group of several bands of medium molecular weight (MW) (30 to 50 kd) and others of low MW (14 to 30 kd); type 2: two or more bands of medium MW; type 3: only one band of medium MW (about 40 kd); type 4: negative blot without any band.

^2^ It is not specified whether each subject was tested with both IgE detection and SPT or only one diagnostic technique.

^3^ The prevalence rate is the result of an inclusion criterion of the study.

Indirect ELISA, ImmunoCAP or RAST were employed in 14 studies on general asymptomatic population; 2 studies among fishing sector workers; 18 studies including symptomatic allergic patients; 5 studies on patients admitted to hospital for any reason; 6 studies on patients with digestive disorders; and 1 study on post-partum women. Two variations of indirect ELISA, that are antigen capture ELISA \[[@pone.0203671.ref047], [@pone.0203671.ref035]\] and rAni s 1, rAni s 7 ELISA \[[@pone.0203671.ref030], [@pone.0203671.ref036], [@pone.0203671.ref042]\], were used, respectively, in 5 studies in the general population and in allergic patients.

Immunoblotting technique was performed along with IgE detection by means of previously cited tests in 4 studies on general asymptomatic population \[[@pone.0203671.ref030], [@pone.0203671.ref014], [@pone.0203671.ref048], [@pone.0203671.ref049]\]; 4 studies on symptomatic population with allergies to any kind of allergen \[[@pone.0203671.ref014], [@pone.0203671.ref030], [@pone.0203671.ref031],[@pone.0203671.ref050]\]; 1 study on patients presenting to hospital for controls \[[@pone.0203671.ref051]\] and 2 studies on patients with digestive system disorders \[[@pone.0203671.ref032], [@pone.0203671.ref049]\].

General asymptomatic population was investigated for *Anisakis* sensitization through SPTs assessment in 4 studies (in 1 case it was the only diagnostic criterion employed \[[@pone.0203671.ref052]\]; in the remaining 3 studies, SPTs were performed along with other IgE detection techniques or CD63 BAT) \[[@pone.0203671.ref014], [@pone.0203671.ref038],[@pone.0203671.ref040]\].

Occupationally exposed workers were assessed for *Anisakis* sensitization by SPTs alone in 1 study \[[@pone.0203671.ref005]\], and by both SPTs and RAST in another one \[[@pone.0203671.ref040]\].

Cutaneous reactivity to *Anisakis* extract among allergic patients was also evaluated in 15 studies, including 10 studies which performed both SPTs and IgE detection through indirect ELISA, ImmunoCAP or radioimmunoassays; SPTs and Immunoblot were present in 3 studies protocols; anamnesis of allergic symptoms correlated to fish consumption was considered along with SPTs in 4 studies; finally, Frezzolini et al. \[[@pone.0203671.ref038]\] added CD63 BAT to SPTs assessment.

Basophil activation test (BAT) was introduced by Gonzalez-Munoz et al. in 2005 \[[@pone.0203671.ref053]\] and later used by Frezzolini et al. \[[@pone.0203671.ref038]\] among allergic patients and healthy controls.

Falcao et al. assessed *Anisakis* sensitization considering the combination of both SPTs and ImmunoCAP positivity in allergic patients and in controls selected for surgery procedures \[[@pone.0203671.ref054]\]. Similarly, a combination of SPTs and IgE detection was performed by Gomez et al. among digestive disorders patients \[[@pone.0203671.ref055]\].

General asymptomatic population resulted sensitized to *Anisakis* in 0.4 to 27.4% of cases by means of indirect ELISA or ImmunoCAP specific IgE detection \[[@pone.0203671.ref014], [@pone.0203671.ref035]\], and between 6.6% and 19.6% of the samples by means of SPTs \[[@pone.0203671.ref014], [@pone.0203671.ref038], [@pone.0203671.ref040], [@pone.0203671.ref052]\]. *Anisakis* antigens recognition patterns were obtained by Immunoblotting assays in 25% \[[@pone.0203671.ref014]\] to 67.5% of sera from asymptomatic general population samples \[[@pone.0203671.ref048]\].

Occupationally exposed workers (fishermen, fishmongers and workers of fish-processing industries) had specific IgE between 11.7% \[[@pone.0203671.ref004]\] and 50% of cases \[[@pone.0203671.ref040]\], whereas SPTs positivity ranged between 8% and 46.4% \[[@pone.0203671.ref005], [@pone.0203671.ref040]\].

Symptomatic allergic patients to any kind of allergen were found to be positive to *Anisakis* specific IgE detection between 0.0% in children with mastocytosis (González de Olano 2007)\[[@pone.0203671.ref056]\] to 81.3% among adults with shellfish allergy (Pascual 1996) \[[@pone.0203671.ref044]\]; diagnostic bands at Immunoblot were visualized in 15--56% of cases (Caballero 2012)\[[@pone.0203671.ref031]\] (Montoro 1997)\[[@pone.0203671.ref050]\]. SPT positivity among allergic individuals (14 studies) ranged from 4.5% out of 10570 suspected allergy patients (Consortium 2011) \[[@pone.0203671.ref021]\] to 64% among 16 patients with acute recidivous urticaria, usually eating fish or other seafood (Montoro 1997) \[[@pone.0203671.ref050]\]. In particular, chronic urticaria patients reacted to skin tests between 14% and 63% (del Pozo 1997) \[[@pone.0203671.ref057]\] (Frezzolini A 2010)\[[@pone.0203671.ref038]\]. The SPT detected also a 14% prevalence of *Anisakis* positivity among atopic subjects (Frezzolini A 2010) \[[@pone.0203671.ref038]\], while it estimated a positivity ranging from 4.5% to 15% in patients presenting to allergological clinics to deal with suspected allergy (Consortium 2011) \[[@pone.0203671.ref021]\] (Heffler E 2016) \[[@pone.0203671.ref058]\]. When considering also anamnestic criteria (symptoms after fish eating), allergy to *Anisakis* was found between in 0.0--14.0% of patients \[[@pone.0203671.ref021], [@pone.0203671.ref056]--[@pone.0203671.ref058]\].

Sensitization rates in 5 study-samples selected from hospital-admitted subjects varied according to different criteria to define AS allergy, from 0.5% with a combination of both positive SPTs and \>0.7 kU/L IgE (Falcão H 2008) \[[@pone.0203671.ref054]\] to 20% when IgE \>0.35 kU/L were sufficient to be considered positive (Daschner A 1998) \[[@pone.0203671.ref059]\].

Six other studies investigated the seroprevalence of specific antibodies against *Anisakis* in patients with digestive system disorders (dyspepsia, appendicits/appendectomized, digestive haemorrage, gastric neoplasms), ranging from 1.3% positive to IgA (Andreu-Ballester JC 2008) \[[@pone.0203671.ref060]\] to 75.4% for IgG (Gutiérrez R 2002) \[[@pone.0203671.ref032]\]. Gomez et al. detected 80% of eosinophilic gastroenteritis (EG) patients positive to *Anisakis* SPTs, but only 10% among subjects who suffered from digestive disorders other than EG \[[@pone.0203671.ref055]\].

Positive immunorecognition pattern of *Anisakis* crude extracts (CE) antigens were found in 24% of sera from patients with symptoms of Crohn's disease and 48% of those with digestive haemorrhaging \[[@pone.0203671.ref032]\].

Finally, IgG positivity was detected in 19.6% of a sample of postpartum women in Brazil (Figueiredo 2015) \[[@pone.0203671.ref061]\].

Discussion {#sec020}
==========

We identified 248 research articles and abstracts after searching various bibliographic databases and grey literature. Forty-one studies comprising 31,701 participants from eleven countries overall were included for qualitative synthesis. Most of the studies were set in high raw fish consuming countries, including Spain (n = 22, 6,734 participants) and Italy, where the largest study samples came from (8 studies comprising 17,059 participants). Also, 2 studies took place in Brazil and Norway, respectively, while 1 study was performed in each one of the following countries: Croatia, Indonesia, Japan, Morocco, Portugal, South Africa and South Korea. All the previous evidences support for a global spread of the investigated health subject.

Indirect ELISA and ImmunoCAP methods resulted the most common techniques used to assess *Anisakis* sensitization by far, measuring the presence of different classes of antibodies against various *Anisakis* allergens. As expected, higher hypersensitivity rates were obtained from selected samples of symptomatic, allergic subjects usually eating raw or undercooked seafood, coherently with the well-known association between *Anisakis* sensitization, urticaria/allergic symptoms and undercooked fish intake \[[@pone.0203671.ref044], [@pone.0203671.ref050]\], while prevalence rates tended to be lower if the study sample size was larger \[[@pone.0203671.ref030],[@pone.0203671.ref062]\], and when diagnostic techniques were targeting fewer but more specific *Anisakis* antigens, or when setting higher positivity threshold for specific antibodies detection.

The results of the studies investigating *Anisakis* sensitization among the general asymptomatic population clearly highlighted the association between fish consumption and *Anisakis* sensitization. Particularly, the two studies with the largest sample size of random healthy subjects, investigated by SPTs and IgE detection, measured *Anisakis* responsiveness in 16% out of 187 individuals \[[@pone.0203671.ref052]\] and 6% out of 1,008, respectively \[[@pone.0203671.ref019]\]. Prevalence rates were greatly affected by *Anisakis* antigens chosen as target of diagnostic tests, with large differences between crude extracts of entire *Anisakis* larvae versus specific recombinant excretory-secretory proteins. More deeply, *Anisakis* larvae crude extracts (CE) might contain several cross-reactive allergens with other nematodes \[[@pone.0203671.ref063]--[@pone.0203671.ref065]\], crustaceans, insects or mites \[[@pone.0203671.ref044], [@pone.0203671.ref066], [@pone.0203671.ref067]\], and their use as target antigens in commercial assays, both serological (ImmunoCAP) and clinical ones (SPT), may lead to less specificity and consequent overestimation of seroprevalence.

Antigen capture ELISA, a variation of indirect ELISA developed to use recombinant antigens Ani s1 and Ani s7, has been applied by two Spanish studies, showing prevalence ranging from 0.4% out of 2,801 individuals \[[@pone.0203671.ref035]\] to 11.7% out of 264 adults \[[@pone.0203671.ref047]\]. Successively, another variation of rAni s1 and rAni s7 indirect ELISA was introduced by Anadon et al. \[[@pone.0203671.ref036]\] representing the most specific serum test to diagnose anisakiasis, revealing IgE in 40.2% out of 493 allergic subjects in Madrid, with respect to 52.7% positivity prevalence measured by ImmunoCAP from the same serum samples. Antigen capture ELISA with rAni s1 and rAni s7 was latter employed in a Croatian setting, determining 2% out of 500 random healthy subjects sampled from different areas with decreasing prevalence from a maximum of 3.5% among individuals living in islands (assumed as high fish consumers) to 1.5% in urban coastal areas, while a 0.0% prevalence was documented in a rural part of the country (declared to be an area of low or absent seafood intake), stressing the association between *Anisakis* sensitization and fish intake \[[@pone.0203671.ref042]\]. Recombinant Ani s1 and rAni s7 indirect ELISA was also used as second-step test to analyse ImmunoCAP positive sera obtained from Norwegian healthy blood donors and selected subjects with \>1000 kU/L total IgE, resulting in prevalence rates of 0.0% and 0.2%, respectively, in comparison with 0.4% and 16.2% ImmunoCAP positivity rates from the same samples. It is not clear whether these findings confirm that significant part of the ImmunoCAP positive sera are false-positive due to cross-sensitization, or due to the unspecific binding of very high total IgE levels, or due to minor presence of *Anisakis* antigens other than rAni s1 and s7 \[[@pone.0203671.ref030]\]. Similar considerations regarding cross-reactivity issues and not univocal diagnostic criteria apply to the 24 studies performed in subjects with immune disorders or presenting to allergology units to rule out suspected allergy. Findings of these studies associated *Anisakis* sensitization to both relapsing acute \[[@pone.0203671.ref054]\] and chronic urticaria \[[@pone.0203671.ref047], [@pone.0203671.ref011]\]; furthermore, allergic manifestation after ingestion of contaminated raw or marinated fish were more frequent when patients were co-sensitized to house dust mites or molds according to SPTs, suggesting possible cross-reactive but clinically relevant allergens between these allergenic sources \[[@pone.0203671.ref058]\].

Generally, SPTs against *Anisakis* crude extracts resulted in wide ranges of positivity prevalence: the two largest studies measured 4.5% SPT+ out of 10570 suspected allergy subjects \[[@pone.0203671.ref021]\] and 15% SPT+ out of 3,410 allergy clinic outpatients \[[@pone.0203671.ref058]\], both percentages decreased to 0.6% and 0.8%, respectively, when allergic symptoms after raw fish intake was added as diagnostic criterion, suggesting how anamnesis plays an important role in pointing out real allergy versus possible cross-reactivity. SPT positivity without clinical manifestation can still be considered an alarm for future allergic reactions after contact with responsible antigens.

As for IgE detection, the largest Japanese study among 2,108 sera of urticaria or food allergy patients revealed 29.8% seroprevalence with a positivity threshold set at \>0.7 kU/L, showing that patients suffering from type I allergic symptoms following ingestion of *Anisakis* parasitized fishes are more often sensitized to *Anisakis* specific allergen than to allergens of the seafood per se \[[@pone.0203671.ref020]\].

Detection of *Anisakis*-induced basophil activation (BAT) by flow cytometry was introduced by Gonzalez-Munoz et al. in 2005 \[[@pone.0203671.ref053]\]. Frezzolini et al. \[[@pone.0203671.ref038]\] latter on compared BAT with SPT and ImmunoCAP in diagnosing *Anisakis* sensitization among chronic urticaria patients, atopic subjects and healthy controls. All three tests had good similar sensitivity, but highest specificity of 100% was reached only by BAT supporting BAT as reliable diagnostic tool for anisakiasis, resulting in sensitization prevalence of 67% among chronic urticaria patients and 0% among healthy subjects.

Prevalence of detectable antibodies against *Anisakis* in six studies on patients with anamnesis of digestive disorders (dyspepsia, appendicitis, digestive haemorrhaging, Crohn's disease, digestive cancer) ranged between 1.3% and 89.4% \[[@pone.0203671.ref032], [@pone.0203671.ref060]\]. However, most studies were of limited sample-size, therefore, no conclusive statement could be drawn in relation of Anisakis sensitization and the reported conditions. Largest sample included 174 dyspeptic patients showing IgE anti Ani s1 in 13.8% of cases. This finding suggests that *Anisakis* infection might be more frequent than expected, since only the most severe cases that require urgent upper endoscopy examination are being diagnosed at present, and because of confounding clinical manifestations with other conditions. Furthermore, uncooked-fish ingestion and previous gastric surgery were confirmed to be significantly associated with seropositivity for specific IgE against Ani s1 antigen by means of immunoblotting \[[@pone.0203671.ref068]\].

Although case-control studies alone are not sufficient to assess causality relationships, the significant higher ratio of positivity to secretory IgA1, rAni s1, or rAni s5 found by Garcia-Perez et al. in 47 gastric cancer patients as compared to 47 healthy controls (38.3% vs 6.4%, p-value \<0.001 and 42.6% vs 10.6%, p-value \<0.001, respectively), together with the evidence that some parasites inducing chronic inflammation may trigger cancer, and that *Anisakis* larvae have been co-localised incidentally in cases of gastro-intestinal tumours, could suggest that Anisakis infection might be a risk factor for the development of digestive tract cancer \[[@pone.0203671.ref033]\]. Parasites gastrointestinal lesions often mimic ulcers, so that patients diagnosed with digestive bleeding may suffer from unrecognized anisakiasis, explaining the high prevalence of specific antibodies and immunoblot bands of *Anisakis* reference serum \[[@pone.0203671.ref032]\]. By contrast, the transitory lower prevalence of anti-*Anisakis* specific immunoglobulins documented in 80 appendectomized patients was explained by a diminution of immune responses against pathogens caused by the resection of an area of the Gut Associated Lymphoid Tissue (GALT) \[[@pone.0203671.ref060]\], even if these results are questionable.

There are no definitive and clear patterns of bands obtained by immunoblotting assays testing for the presence of specific anti-*Anisakis* IgE. One possible explanation of large differences in molecular weights of the bands detected by immunoblotting may be the lack of unanimous preparation of *Anisakis* antigenic extracts and the different blotting conditions, which may vary the number of obtained proteins.

Immunoblotting assays were also used as second-step analysis to rule out cross-reactivity among selected sera which resulted in an already positive to *Anisakis* at ImmunoCAP or ELISA, with miscellaneous results \[[@pone.0203671.ref030], [@pone.0203671.ref031],[@pone.0203671.ref052]\]. Most of tested sera were positive to *Anisakis* crude extracts at Immunoblot, but recognized patterns of bands were not univocal and not always concordant with the human anisakiasis reference serum (E1) \[[@pone.0203671.ref030], [@pone.0203671.ref052]\].

We have further analysed the studies dealing with occupationally exposed groups of fishermen, fishmongers and fishing industry workers who are in frequent contact with raw fish and consequently with *Anisakis* larvae \[[@pone.0203671.ref004],[@pone.0203671.ref005],[@pone.0203671.ref040]\]. Larger study samples resulted in lower sensitization prevalence: SPTs were positive in 8% out of 578 fish industry workers according to Nieuwenhuizen et al. \[[@pone.0203671.ref005]\] versus 46.4% out of only 28 fishermen/fishmongers in Purello-D'Ambrosio study \[[@pone.0203671.ref040]\]. Anisakis specific IgE were detected in 11.7% out of 94 fish sector workers by means of UniCAP-100 \[[@pone.0203671.ref004]\] and 50% out of 28 subjects by means of RAST \[[@pone.0203671.ref040]\], with antibody levels increasing with duration of occupational exposure. Being at higher risk for sensitization, fishing sector workers can represent ideal candidate for screening and development of better diagnostic tools with ameliorated sensitivity and specificity, to be successively extended in the general population.

Even if we did not perform a quantitative metanalysis, all studies which compared prevalence rates between random healthy subjects and suspected allergic or digestive disorders patients or occupationally exposed workers tended to show lower responsiveness in the former group. The wide heterogeneity in study samples characteristics, design, settings, diagnostic techniques and criteria to define *Anisakis* sensitization or allergy along with the lack of important information in a large number of studies prevented us to summarize data in order to perform a metanalysis of prevalence results.

Also, from our systematic review important weaknesses emerged referring to the quality of studies available from literature. In fact, most of the studies were not conducted on samples representative of the general population, as the sample size was not calculated a priori to accurately infer sensitization prevalence among the population of origin. A random sampling was never performed, being most of the studies conducted on a convenience sample and the response rate almost never reported. Moreover, in the few studies providing complete details on study population, especially random sera samples were often missing any information about subjects' gender and age.

Importantly, not all studies specified target antigens of ELISA and UniCAP methods, giving only general information about specific anti-*Anisakis* IgE detection.

For the previous reasons, comparisons to rule out cross-reactivity influence or differences in specificity and sensitivity were not possible.

Furthermore, correlation between anisakiasis prevalence among different countries with fish parasitism rates of surrounding waters is not straightforward, as nowadays global trading makes seafood from very distant areas easily available. However, high fish consuming habits and genetic susceptibility linked to the presence of DRB1\*1502-DQB1\*0601 haplotype \[[@pone.0203671.ref069]\] could partially explain the widespread geographical variety observed \[[@pone.0203671.ref021],[@pone.0203671.ref042],[@pone.0203671.ref068]\].

Low sensitization prevalence among Norwegian blood donors and subjects with \>1,000 kU/L total IgE despite frequent seafood intake can be explained by the absence of genetical susceptibility haplotype and by the consumption of mainly processed, canned, frozen and farmed Atlantic salmon (which was demonstrated not to be infected from anisakid nematodes) \[[@pone.0203671.ref030],[@pone.0203671.ref070]\].

Lastly, as confirmed by several authors, Anisakis sensitization can be induced by ingestion of well-cooked contaminated fish due to thermo- and pepsin-resistant allergens \[[@pone.0203671.ref054], [@pone.0203671.ref059],[@pone.0203671.ref071], [@pone.0203671.ref072]\], showing a residual allergenic activity also after specific heat treatment \[[@pone.0203671.ref073]\].

Conclusion {#sec021}
==========

This systematic review has highlighted the epidemiological impact of *Anisakis* as hypersensitivity aetiologic factor in the general population from several countries worldwide, also with regard to specific groups of patients and occupationally exposed subjects. We observed that hypersensitivity prevalence estimates varied widely according to geographical area, characteristics of the population studied, diagnostic criteria and laboratory assays with varying sensitivity and specificity. Our findings made us conclude that, if, on one hand, *Anisakis* represents a hidden cause of many adverse reactions after eating undercooked seafood, which are often claimed to be "fish allergy", including chronic idiopathic urticaria, on the other hand, further studies are needed to overcome the documented misdiagnosis by improving the diagnostic approach and, consequently, to provide more affordable estimates in order to address public health interventions on populations at high risk of exposure to *Anisakis* and to tailor health services related to specific groups.
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PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

AS

:   Anisakis

ELISA

:   enzyme-linked immunosorbant assay

MeSH

:   Medical Subject Headings

SPT

:   Skin prick test

RAST

:   Radio-Allergo-Sorbent Test

OD

:   optical density

BAT

:   Basophil activation test

EG

:   eosinophilic gastroenteritis

CE

:   crude extracts

ES

:   excretory-secretory

GALT

:   Gut Associated Lymphoid Tissue
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